• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Therapeutic advances in HBV cure.

作者信息

Hui Rex Wan-Hin, Mak Lung-Yi, Seto Wai-Kay, Yuen Man-Fung

机构信息

Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR.

State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR.

出版信息

Clin Liver Dis (Hoboken). 2024 Apr 15;23(1):e0161. doi: 10.1097/CLD.0000000000000161. eCollection 2024 Jan-Jun.

DOI:10.1097/CLD.0000000000000161
PMID:38623151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11018176/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd3c/11018176/80eb5227efd6/xcl-23-e0161-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd3c/11018176/80eb5227efd6/xcl-23-e0161-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd3c/11018176/80eb5227efd6/xcl-23-e0161-g001.jpg

相似文献

1
Therapeutic advances in HBV cure.乙肝治愈方面的治疗进展。
Clin Liver Dis (Hoboken). 2024 Apr 15;23(1):e0161. doi: 10.1097/CLD.0000000000000161. eCollection 2024 Jan-Jun.
2
Meeting the Challenge of Eliminating Chronic Hepatitis B Infection.消除慢性乙型肝炎感染的挑战。
Genes (Basel). 2019 Apr 1;10(4):260. doi: 10.3390/genes10040260.
3
Present and future therapies of hepatitis B: From discovery to cure.乙型肝炎的当前及未来疗法：从发现到治愈
Hepatology. 2015 Dec;62(6):1893-908. doi: 10.1002/hep.28025. Epub 2015 Oct 27.
4
Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy.基于核苷（酸）类似物的联合治疗中，天门冬氨酸氨基转移酶升高对乙型肝炎病毒感染功能性治愈的获益。
J Viral Hepat. 2021 May;28(5):817-825. doi: 10.1111/jvh.13483. Epub 2021 Feb 26.
5
Challenges for hepatitis B virus cure in resource-limited settings in sub-Saharan Africa.撒哈拉以南非洲资源有限地区实现乙型肝炎病毒治愈的挑战。
Curr Opin HIV AIDS. 2020 May;15(3):185-192. doi: 10.1097/COH.0000000000000619.
6
Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.靶向固有和适应性免疫系统以治愈慢性乙型肝炎病毒感染的研究进展。
Front Immunol. 2020 Feb 7;10:3127. doi: 10.3389/fimmu.2019.03127. eCollection 2019.
7
HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.HBsAg 消失作为慢性 HBV 感染的治疗终点：HBV 治愈。
Viruses. 2022 Mar 22;14(4):657. doi: 10.3390/v14040657.
8
Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review.功能性治愈乙型肝炎病毒感染合并 HIV 感染个体：文献综述。
Viruses. 2021 Jul 11;13(7):1341. doi: 10.3390/v13071341.
9
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.实现慢性乙型肝炎的完全治愈：乙型肝炎病毒的新治疗靶点。
Clin Mol Hepatol. 2022 Jan;28(1):17-30. doi: 10.3350/cmh.2021.0093. Epub 2021 Jul 20.
10
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?如何实现乙肝功能性治愈：停止核苷（酸）类似物，加用干扰素或开发新药？
J Hepatol. 2022 Jun;76(6):1249-1262. doi: 10.1016/j.jhep.2021.11.024.

引用本文的文献

1
Evaluation of fully automated chemiluminescent enzyme immunoassays for hepatitis B core-related antigen components, phosphorylated and non-phosphorylated hepatitis B core antigens: clinical significance and dynamics during hepatitis B e antigen seroconversion.评估用于检测乙型肝炎核心相关抗原成分、磷酸化和非磷酸化乙型肝炎核心抗原的全自动化学发光酶免疫分析法：乙型肝炎e抗原血清学转换期间的临床意义及动态变化
J Clin Microbiol. 2025 Sep 10;63(9):e0038525. doi: 10.1128/jcm.00385-25. Epub 2025 Aug 19.
2
Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates.抗乙型肝炎病毒的高级 siRNA 递呈：机制见解和最新进展。
J Nanobiotechnology. 2024 Nov 30;22(1):745. doi: 10.1186/s12951-024-03004-3.

本文引用的文献

1
Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.在病毒抑制的慢性乙型肝炎个体中口服 TLR8 激动剂 selgantolimod 的安全性和疗效。
J Hepatol. 2023 Mar;78(3):513-523. doi: 10.1016/j.jhep.2022.09.027. Epub 2022 Oct 29.
2
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.JNJ-73763989 与 JNJ-56136379（贝沙卡韦）联合核苷（酸）类似物治疗慢性乙型肝炎病毒感染的疗效和安全性（REEF-1）：一项多中心、双盲、活性对照、随机、2b 期临床试验。
Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10.
3
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.慢性丁型肝炎的布乐瑞肽 3 期随机临床试验。
N Engl J Med. 2023 Jul 6;389(1):22-32. doi: 10.1056/NEJMoa2213429. Epub 2023 Jun 22.
4
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.慢性乙型和丁型肝炎临床治愈临床试验终点和研究设计指导：2022 年 AASLD-EASLHBV-HDV 治疗终点会议报告。
Hepatology. 2023 Nov 1;78(5):1654-1673. doi: 10.1097/HEP.0000000000000431. Epub 2023 Jun 21.
5
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.比匹韦林治疗慢性乙型肝炎感染的疗效和安全性
N Engl J Med. 2022 Nov 24;387(21):1957-1968. doi: 10.1056/NEJMoa2210027. Epub 2022 Nov 8.
6
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials.评估乙型肝炎治疗中不断发展的药物治疗领域：关注处于 II 期临床试验阶段的药物。
Expert Opin Emerg Drugs. 2022 Jun;27(2):127-140. doi: 10.1080/14728214.2022.2074977. Epub 2022 May 15.
7
RNA interference as a novel treatment strategy for chronic hepatitis B infection.RNA 干扰作为慢性乙型肝炎感染的一种新的治疗策略。
Clin Mol Hepatol. 2022 Jul;28(3):408-424. doi: 10.3350/cmh.2022.0012. Epub 2022 Feb 17.
8
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.48周的REP 2139或REP 2165、替诺福韦酯和聚乙二醇化干扰素α-2a在初治慢性乙型肝炎病毒感染患者中的安全性和疗效
Gastroenterology. 2020 Jun;158(8):2180-2194. doi: 10.1053/j.gastro.2020.02.058. Epub 2020 Mar 6.